Quince Therapeutics (QNCX) hit with dual Nasdaq listing deficiency notices

Rhea-AI Filing Summary

Quince Therapeutics, Inc. has received two deficiency notices from Nasdaq regarding its continued listing on the Nasdaq Global Select Market. Nasdaq notified the company that its common stock failed to meet the $1.00 minimum bid price requirement for 30 consecutive business days, giving Quince until September 14, 2026 to regain compliance by maintaining a closing bid of at least $1.00 for at least ten consecutive business days.

The company also received a notice that its market value of listed securities has been below the required $50,000,000 for 30 consecutive business days, with the same compliance deadline and ten-day cure standard. Quince may seek to transfer to the Nasdaq Capital Market or consider actions such as a reverse stock split, and it can appeal any delisting determination. For now, its stock continues to trade on the Nasdaq Global Select Market under the symbol QNCX.

Positive

• None.

Negative

• Received dual Nasdaq deficiency notices for both minimum bid price below $1.00 and market value of listed securities under $50,000,000, creating a clear risk of eventual delisting if compliance is not restored by September 14, 2026.

Insights

Equity listing & capital markets analyst

Nasdaq deficiency notices raise delisting risk but allow time to cure.

Quince Therapeutics now faces two separate Nasdaq compliance issues: the shares have traded below the $1.00 minimum bid price, and the company’s market value of listed securities has been under $50,000,000 for 30 consecutive business days. Both are explicit thresholds for the Nasdaq Global Select Market.

The company has until September 14, 2026 to restore compliance by meeting each requirement for at least ten consecutive business days, with Nasdaq able to extend that window to twenty days. If it cannot, the stock could be delisted unless Quince either transfers to the Nasdaq Capital Market or successfully appeals to a Nasdaq Listing Qualifications Panel.

Management states it is monitoring its bid price and MVLS and may consider options including a reverse stock split to address the price deficiency. Actual outcomes will depend on market performance and any corporate actions taken before the compliance deadline.

false 0001662774 0001662774 2026-03-16 2026-03-16

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 16, 2026

QUINCE THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-38890		90-1024039
(State or other jurisdiction of incorporation or organization)		(Commission File Number)		(I.R.S. Employer Identification No.)

611 Gateway Boulevard, Suite 273 South San Francisco, California		94080
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (415) 910-5717

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13d-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.001 per share		QNCX		Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

ITEM 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

Minimum Bid Price Requirement

On March 16, 2026, Quince Therapeutics, Inc. (the “Company”) received a notice (the “Bid Price Notice”) from the Nasdaq Listing Qualifications department (the “Staff”) of the Nasdaq Stock Market LLC (“Nasdaq”) stating that the closing bid price of the Company’s common stock for the last 30 consecutive business days had closed below the minimum $1.00 per share required for continued listing under Listing Rule 5450(a)(1) (the “Minimum Bid Price Requirement”). The Company has a period of 180 calendar days, or until September 14, 2026 (the “Compliance Date”), to regain compliance with the Minimum Bid Price Requirement.

To regain compliance, the bid price of the Company’s common stock must close at $1 or more for a minimum of ten consecutive business days before the Compliance Date. Nasdaq may, in its discretion, require the Company to maintain the minimum bid price for a period in excess of ten consecutive business days, but generally no more than 20 consecutive business days, before determining that the Company has demonstrated an ability to maintain long-term compliance.

If the Company does not regain compliance with the Minimum Bid Price Requirement by the Compliance Date, the Company may be eligible for additional time to regain compliance. To qualify, the Company would be required to transfer the listing of its common stock to the Nasdaq Capital Market, provided that the Company meets the continued listing requirement for market value of publicly held shares and all other initial listing standards for the Nasdaq Capital Market (including the market value of listed securities), with the exception of the Minimum Bid Price Requirement. To effect such a transfer, among other things, the Company would also need to pay an application fee to Nasdaq and provide written notice to the Staff of its intention to cure the deficiency during the additional compliance period by effecting a reverse stock split, if necessary. If the Company does not regain compliance with the Bid Price Rule by the Compliance Date and it appears to the Staff that the Company will not be able to regain compliance with the Bid Price Rule during the additional compliance period, or if the Company is otherwise not eligible for an additional compliance period at that time, the Staff will provide written notification to the Company that its common stock will be subject to delisting. At that time, the Company may appeal the Staff’s delisting determination to a Nasdaq Listing Qualifications Panel, but there can be no assurance that the panel would grant the Company’s request for continued listing.

The Company intends to actively monitor the closing bid price for its common stock and will consider available options to resolve the deficiency and regain compliance with Nasdaq Listing Rule 5450(a)(1).

Market Value of Listed Securities Requirement

On March 17, 2026, the Company received a notice (the “MVLS Notice” and together with the Bid Price Notice the “Notices”) from the Staff that the Company’s market value of listed securities (“MVLS”) for the last 30 consecutive business days was less than the $50,000,000 required for continued listing on the Nasdaq Global Select Market under Listing Rule 5450(b)(2)(A) (the “MVLS Requirement”). The Company has a period of 180 calendar days, or until September 14, 2026 (the “MVLS Compliance Date”), to regain compliance with the MVLS Requirement.

To regain compliance with the MVLS Requirement, the Company’s MVLS must close at $50,000,000 or more for a minimum period of ten consecutive business days. Nasdaq may, in its discretion, require the Company to maintain the minimum MVLS for a period in excess of ten consecutive business days, but generally no more than 20 consecutive business days, before determining that the Company has demonstrated an ability to maintain long-term compliance.

In the event the Company does not regain compliance with the MVLS Requirement prior to the MVLS Compliance Date, the Company will receive written notification that the Company’s securities are subject to delisting. At that time, the Company may appeal the delisting determination to a Nasdaq Listing Qualifications Panel, but there can be no assurance that the panel would grant the Company’s request for continued listing. Alternatively, the Company may consider applying to transfer the listing of the Company’s securities to the Nasdaq Capital Market, provided that the Company then satisfies the requirements for continued listing on that market.

The Company is monitoring the MVLS of its listed securities and is considering available options to regain compliance with Nasdaq’s continued listing standards. There can be no assurance that the Company will be able to regain compliance with Nasdaq Listing Rule 5450(b)(2)(A) or maintain compliance with other applicable Nasdaq listing requirements.

The Notices do not result in the immediate delisting of the Company’s common stock, and the Company’s common stock will continue to trade uninterrupted on the Nasdaq Global Select Market under the symbol “QNCX”.

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

				Quince Therapeutics, Inc.
				By:		/s/ Dirk Thye
Date: March 20, 2026				Name:		Dirk Thye
				Title:		Chief Executive Officer

2

FAQ

What Nasdaq listing issues did Quince Therapeutics (QNCX) disclose?

Quince Therapeutics disclosed it received two Nasdaq notices: one for its stock trading below the $1.00 minimum bid price, and another for market value of listed securities falling under $50,000,000 for 30 consecutive business days.

How long does Quince Therapeutics (QNCX) have to regain Nasdaq compliance?

Quince Therapeutics has until September 14, 2026 to regain compliance with both the minimum $1.00 bid price and $50,000,000 market value of listed securities, by meeting each standard for at least ten consecutive business days.

What happens if Quince Therapeutics fails to meet Nasdaq requirements by the deadline?

If Quince Therapeutics does not regain compliance by September 14, 2026, Nasdaq staff may move to delist its common stock. The company could then appeal to a Nasdaq Listing Qualifications Panel, but approval of continued listing is not assured.

Can Quince Therapeutics move its listing to another Nasdaq market?

Quince Therapeutics may seek to transfer its common stock to the Nasdaq Capital Market if it meets that market’s initial and continued listing standards, other than the minimum bid price, and pays applicable fees while pursuing steps, potentially including a reverse stock split.

Is Quince Therapeutics (QNCX) still trading on Nasdaq after these notices?

Yes. Despite the deficiency notices, Quince Therapeutics’ common stock currently continues to trade uninterrupted on the Nasdaq Global Select Market under the symbol QNCX while the company works within the compliance period.

What options is Quince Therapeutics considering to address Nasdaq non-compliance?

Quince Therapeutics states it is actively monitoring its closing bid price and market value of listed securities and will consider available options, which may include a reverse stock split, to resolve the deficiencies and attempt to regain compliance with Nasdaq rules.

Filing Exhibits & Attachments

3 documents

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA 2.8 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE 17.6 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE 11.0 KB